OcellO offers a unique screening platform for Autosomal Dominant Polycystic Kidney Disease (ADPKD). This assay uses PKD1-/- cells in a 3D environment, enabling the recapitulation of the in vivo disease phenotype.

Key advantages:

  • ·      High throughput testing of compounds
  • ·      High content phenotypic evaluation by 3D imaging
  • ·      Separation of toxic from effective compounds
  • ·      Sensitive and robust functional read-outs
  • ·      Optimal in vitro to in vivo translation

Technological highlights:

Murine PKD1-/- collecting duct cells develop into cysts over time when cultured in OcellO’s optimized 3D environment. cAMP- dependent cyst swelling is driven by the addition of Forskolin. Compounds of interest are added to investigate their ability to inhibit the cAMP induced cyst swelling. Cultures are imaged and morphometric analysis is performed on reconstituted intact 3D image stacks.

PKD nucleus PKD nucleus mask PKD actin PKD actin mask
Forskolin Forskolin Forskolin Forskolin
Nuclei image Nuclei mask Actin image Actin mask
Features that are measured include cyst size, thickness of the cyst wall, cyst roundness, nucleus count and nucleus fragmentation (apoptosis), allowing the discrimination of toxic and therapeutically effective compounds.
PKD barchart PKD dose curve
PKD1 -/- mouse collecting duct cells were cultured in 3D. After 4 days, cultures were exposed to Forskolin with reference compounds for 72h. Left panel: 4 reference compounds were compared to positive control (0.2% DMSO) and negative control (Forskolin only) for their capability to inhibit the cyst swelling. Right panel: Dose curves of 2 reference compounds

This high throughput platform is suitable for the profiling of single compounds, ranking of leads and screening of libraries. For more information, please contact us at [email protected]